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Abstract
Background: Botulism, an often fatal neuroparalytic disease, is caused by botulinum neurotoxins (BoNT) which consist of a
family of seven serotypes (A-H) produced by the anaerobic bacterium Clostridium botulinum. BoNT, considered the most
potent biological toxin known, is a 150 kDa protein consisting of a 100 kDa heavy-chain (Hc) and a 50 kDa light-chain (Lc).
F1-40 is a mouse-derived, IgG1 monoclonal antibody that binds the light chain of BoNT serotype A (BoNT/A) and is used in a
sensitive immunoassay for toxin detection. We report the fine epitope mapping of F1-40 and the deduced amino acid
sequence of the variable regions of the heavy and light chains of the antibody.
Methods and Findings: To characterize the binding epitope of F1-40, three complementary experimental approaches were
selected. Firstly, recombinant peptide fragments of BoNT/A light-chain were used in Western blots to identify the epitope
domains. Secondly, a peptide phage-display library was used to identify the specific amino acid sequences. Thirdly, the
three-dimensional structure of BoNT/A was examined in silico, and the amino acid sequences determined from the phage-
display studies were mapped onto the three-dimensional structure in order to visualize the epitope. F1-40 was found to
bind a peptide fragment of BoNT/A, designated L1-3, which spans from T125 to L200. The motif QPDRS was identified by
phage-display, and was mapped to a region within L1-3. When the three amino acids Q138, P139 and D140 were all
mutated to glycine, binding of F1-40 to the recombinant BoNT/A light chain peptide was abolished. Q-138, P-139 and D-140
form a loop on the external surface of BoNT/A, exposed to solvent and accessible to F1-40 binding.
Conclusions: The epitope of F1-40 was localized to a single exposed loop (ß4, ß5) on the Lc of BoNT. Furthermore amino
acids Q138, P139 and D140 forming the tip of the loop appear critical for binding.
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Introduction
Botulinum neurotoxins (BoNTs), the causative agents of
botulism, are the most potent naturally-occurring toxins known
[1]. Seven different serotypes of BoNT, designated A to G, are
produced predominantly by strains of Clostridium botulinum, but also
by some strains of C. butyricum and C. baratii [2]. Each serotype is
further divided into one or more subtypes based upon strain of
origin, resulting in over 40 immunologically distinct BoNT types
[3]. BoNT/A (subtype A1), derived from the Hall strain of C.
botulinum (ATCC 3502), is possibly the most widely studied and
best understood of the BoNTs, and is used in this study.
BoNT is released following bacterial lysis as a 900 kDa complex
in association with several non-toxic accessory proteins (NAPs) [4].
The BoNT/A holotoxin is comprised of a 100 kDa heavy chain
(Hc) and a 50 kDa light chain (Lc), linked by a single disulphide
bond. The Hc functions by binding nerve cells and facilitates the
internalization of the Lc, a zinc endopeptidase that cleaves
SNARE (soluble N-ethylmaleimide sensitive factor attachment
receptor) proteins. This action prevents the release of acetylcholine
from the neuron into the neuromuscular junction, ultimately
resulting in flaccid paralysis of the muscle [5,6]. The three-
dimensional structure of the BoNT/A holotoxin has been
determined at 3.3 A ˚ resolution [7].
In mice, an LD50 of 10 pg per organism was reported for
BoNT/A when administered by inter-peritoneal injection [8].
Early studies estimated a minimum human lethal dose (LD100)o f
BoNT/A at 1 ng per kg body mass when administered via inter-
peritoneal injection [9], but it has since been recognized that the
route of toxin exposure is critical in determining its lethality. For
example, the human LD100 for BoNT/A is estimated at 1 mg/kg
when administered orally, whereas via intravenous injection, the
LD100 is 700-fold lower [10,11].
Although outbreaks of foodborne BoNT poisoning are rare,
their impact can be significant. In July 2007, four cases of
foodborne botulism were linked to the consumption of hotdog chili
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products in 49 states, at a projected cost to the manufacturer of
$35 million [12–14]. BoNT has been used in, or developed for
biological weapons since the 1930’s, and is still considered a
credible threat to national security today, being classified as a Class
A bioterrorism agent by the CDC [15,16]. It has been suggested
that the most likely terrorist strategy would be to contaminate
large batches of food or beverages with BoNT. One study
described a mathematical model of where milk was intentionally
adulterated [17].
These concerns demonstrate the need for tests to detect the
presence of toxin in food. Such tests must be easily completed with
a minimum amount of sample preparation, they should be
sensitive, specific, and give accurate results in a timely manner.
Despite the range of tests that have or are being developed, most
require a skilled technician to prepare the sample and perform the
test, and can take from several hours to four days to obtain results
(for full reviews see [18,19]). We recently reported the develop-
ment and partial characterization of four high-affinity monoclonal
antibodies (mAbs), designated F1-2, F1-5, F1-40 and F2-43, to
BoNT/A from the Hall strain of C. botulinum [20]. Two of these
mAbs, F1-2 and F1-40, were used to develop a sensitive sandwich-
ELISA with a detection limit of 2 pg/mL, approximately 10-fold
more sensitive than the mouse bioassay. Since F1-40 is used in this
sensitive ELISA, molecular characterization and a detailed
understanding of its binding properties are highly desirable to
develop improved assays and enhance the predictive value of this
diagnostic test. For example, F1-40 exhibits high affinity binding
to the light chain of BoNT/A1, but other serotypes are not
detected [20]. Understanding the molecular basis of this specificity
would improve our ability to incorporate F1-40 into multianalyte
assays able to detect more than a single serotype. In addition to
development of improved diagnostics, mapping antibody epitopes
onto the toxin is extending our understanding of the mechanisms
by which antibodies, individually or in combinations, neutralize
toxin [21,22]. Preliminary data indicates that F1-40, by itself or as
a component of a multi-antibody mixture is effective in protecting
mice from BoNT/A [23]. Thus, characterization of the F1-40
epitope may help elucidate the mechanism by which it neutralizes
the toxin. Furthermore, since F1-40, in a mouse model, was able to
rescue animals after intoxication, cloning and sequencing the
antibody heavy and light chain variable regions represents the first
step in further engineering of this antibody.
In this article, we report the identification of the F1-40 epitope
on the light chain of BoNT/A using three complementary
experimental approaches. Firstly, antibody binding to recombi-
nant peptide fragments of BoNT/A light-chain was investigated.
Secondly, a peptide phage-display library was used to identify
amino acid sequences that were bound by F1-40. Thirdly the
three-dimensional structure of BoNT/A was examined in silico,
and the ligands determined from the phage-display studies were
mapped onto the three-dimensional structure in order to visualize
a putative epitope. Mutagenesis studies were used to confirm the
identified epitope. In an effort to further characterize mAb F1-40,
the variable regions gene sequences of the heavy and light chains
were determined, and the amino acid sequences of the
complementary determining regions deduced.
Methods
Plasmid construction
Commercial enzymes (Phusion High-Fidelity DNA Polymerase,
BamHI, XhoI, T4 polynucleotide kinase [39 phosphatase minus],
T4 DNA ligase [New England BioLabs Inc., Bethesda, MD]) were
used according to the manufacturer’s recommendation. Primers
used were purchased from Integrated DNA Technologies (Coral-
ville, IA) and are shown in Table 1. Plasmid construction and
manipulation was performed in Escherichia coli TOP10 cells
(Invitrogen, Carlsbad, CA) grown aerobically in Luria-Bertani
(LB) medium at 37uC supplemented with 100 mg/mL ampicillin
[24]. Plasmids or DNA were purified using the QuickClean 5M
range of kits (GenScript Corp., Piscataway, NJ). All automated
DNA sequencing was performed using the Big Dye Terminator
Version 3.1 and XTerminator reagents, and a 3730 DNA
Analyzer (Applied Biosystems, Foster City, CA).
Total genomic DNA from Clostridium botulinum (Strain
ATCC3502) was used as a template to amplify the fragments of
the light chain (Lc, L1, L2) using the primers indicated (see
Figure 1 and Table 1). Stop codons (TAA) were introduced when
not present within the genomic DNA of the cloned region. All
subsequent BoNT/A DNA fragments were cloned into plasmid
pCR4-TOPO (Invitrogen) to allow sequencing using primers
M13F and M13R. The pCR4-derived plasmids were then digested
using BamHI and XhoI, the BoNT/A fragment was purified and
ligated into BamHI- and XhoI-digested pGS-21a (Genscript) to
yield the correspondently named pGS plasmid (e.g. pGS-L1 for
fragment L1). All pGS-21a-derived plasmids were sequenced using
primer pGS-F and pGS-R, to confirm the correct integration of
the BoNT/A fragment into the vector. The BamHI and XhoI
cloning sites of pGS-21a are located downstream of glutathione-S-
transferase (GST), under the control of the T7 promoter.
Plasmids pGS-L1-1 through pGS-L1-4 were constructed by
PCR using plasmid pGS-L1 as a template. Primers were used to
amplify outwards from the L1 region, thus eliminating internal
pieces of L1 (see Figure 1). The PCR product was gel purified,
treated with T4 polynucleotide kinase then self-ligated to form an
intact plasmid. The mutant plasmids pGS-Lc-D, pGS-Lc-QPD
and pGS-Lc-RS (see Table 2) were constructed by PCR in an
identical manner, using plasmid pGS-Lc as a template, and the
primers shown in Table 1.
Expression and purification of GST-fusion proteins
All pGS-21a-derived plasmids were transformed into E. coli
BL21-CodonPlus (DE3)-RIPL cells (Stratagene, La Jolla, CA), and
grown aerobically on LB agar at 37uC supplemented with 100 mg/
mL ampicillin and 75 mg/mL streptomycin. Single colonies were
grown overnight in LB containing the same antibiotics and 0.5%
glucose, to minimize uninduced expression of the fusion protein
[25]. An inoculum of 6 mL was added to 600 mL 2YT medium
(1% tryptone, 1.6% yeast extract, 0.5% NaCl) containing the same
antibiotics and glucose, and the culture was grown aerobically at
30uC with 200 rpm agitation to an OD600 of ,0.6. Expression
was induced with 1 mM IPTG (isopropyl ß-D-1 thiogalactopyr-
anoside), the culture was grown overnight at 18uC and cells were
harvested by centrifugation at 100006g for 10 min.
The cell pellet was suspended in 10 mL lysis solution (PBS
[10 mM phosphate buffer, 138 mM NaCl, 2.7 mM KCl, pH 7.4],
1 mM PMSF (phenylmethanesulphonylfluoride), 0.2 mg/mL
lysozyme, 16 CelLytic-B Cell Lysis Reagent, 0.5 mL Benzonase
Nuclease [Sigma-Aldrich Inc., St. Louis, MO]) and incubated at
37uC for 10 min with 200 rpm agitation, then placed immediately
on ice. The lysate was clarified by centrifugation at 128006g for
15 min, then loaded directly onto a column of High-Affinity GST
Resin (1 mL bed volume; Genscript) that had been equilibrate
with 20 bed volumes ice-cold PBS containing 1 mM PMSF. The
column was washed with 30 bed volumes ice-cold PBS-PMSF and
then eluted with 15 bed volumes of elution buffer (10 mM reduced
glutathione, 50 mM Tris, pH 8.0) in fractions of 1 mL.
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All gel electrophoresis equipment, buffers, gels and nitrocellu-
lose membranes were purchased from PAGEgel (San Diego, CA).
Samples of 40 mL (25 mL protein sample, 10 mL4 6 gel buffer,
4 mL 1 M dithiothreitol) were heated for 10 min at 70uC, then
loaded onto a 10% gel and separated by electrophoresis at 175 V
(constant) for 80 min. For protein visualization, gels were silver
stained using the Silver Express kit (Invitrogen) according to
manufacturer’s instructions. For Western blotting, the gel was
subjected to horizontal blotting onto a nitrocellulose membrane
using a PAGEgel transfer cell (180 mA constant, 100 min).
Membranes were incubated in blocking buffer (16 PBS-T [PBS
plus 0.05% Tween-20], 3% non-fat dried milk) for 1 hr at room
temperature with gentle agitation. Membranes were incubated
for 1 hr at 37uC with gentle agitation in primary antibody (F1-
40 or a rabbit polyclonal to Clostridium botulinum A toxoid #
20641 [Abcam Inc., Cambridge, MA]) diluted 5 mg/mL in
10 mL of blocking buffer. Membranes were washed 4 times in
PBS-T. Membranes were incubated for 1 hr at room temper-
ature with gentle agitation in secondary antibody diluted 1:5000
in blocking buffer. Peroxidase-conjugated, goat anti-mouse IgG
#A4416 was used to detect F1-40; peroxidase-conjugated, goat
anti-rabbit IgG #A6154 was used to detect the polyclonal
antibody (Sigma-Aldrich). Membranes were washed 4 times in
PBS-T, then SuperSignal West Dura Extended Duration
Substrate (Pierce, Rockford, IL) was added according to
manufacturer’s instructions. Membranes were visualized using
a Fluorchem SP unit (Alpha Innotech Corp., San Leandro, CA).
Competition ELISA
Black 96-well plates were coated with the Lc-GST fusion
peptide by adding 100 mL per well of a 4 mg/mL solution of Lc
peptide in 0.05 M carbonate buffer (pH 9.6) and incubating
overnight at 4uC. Plates were then blocked by adding 300 mL
blocking buffer (16PBS-T [PBS plus 0.05% Tween-20], 3% non-
fat dried milk) to each well and incubating for 1 hr at room
temperature. Wells were filled with 100 mL blocking buffer
containing decreasing concentrations (120, 60, 30, 15, 7.5, 3.75,
1.88, 0.94, and 0 mg/mL) of a fusion peptide in solution (Lc, Lc-D,
Lc-QPD or Lc-RS) and then 100 mLo fa5mg/mL solution of F1-
40 was immediately added to each well. Plates were incubated
overnight at 4uC with gentle agitation, then washed 12 times in
PBS-T. Next, 200 mL of peroxidase-conjugated goat anti-mouse
IgG #A4416 (Sigma-Aldrich) diluted 1:5000 in blocking buffer
was added to each well and the plate incubated for 1 hr at room
temperature with gentle agitation. Plates were washed 12 times in
Table 1. Primers.
Primer Sequence Constructs
LcF GGATCCATGCCATTTGTTAATAAACAATTTAATTATAAAG Lc, L1
LcR CTCGAGTTATTTAGAAGTTATTATCCCTCTTACAC Lc, L2
L1R CTCGAGTTAAAGTGACTCCTCAAAACCAAATG L1
L2F GGATCCGAAGTTGATACAAATCCTCTTTTAG L2
GS-L GGATCCGATATCAGCCATGGCC L1-3, L1-4
GS-R TAACTCGAGCACCACCACCAC L1-1,L1-2
L1b TTCTGGTGGTGGATTTAAATCTCCTTC L1-1
L1c GCAAAACAAGTTCCAGTTTCATATTATGATTC L1-4
L1d ATCTATTGTACTTCCACCCCAAAATGG L1-2
L1e ACAGAATTAAAAGTTATTGATACTAATTGTATTAATGTG L1-3
Lc-DL ATTAGTATCAATAACTTTTAATTCTGT Lc-D
Lc-DR CTTAATCTAGTAATAATAGGACCCT Lc-D
Lc-QPDL ACCACCTATCACATTAATACAATTAGTATCAAT Lc-QPD
Lc-QPDR GGTGGTAGTTATAGATCAGAA Lc-QPD
Lc-RSL ACCATAACTACCATCTGGTTGTATCA Lc-RS
Lc-RSR GGAGAAGAACTTAATCTAGTAATAATA Lc-RS
L-chainR TCTAGAACTGGATGGTGGGAGATGGA F1-40 L-chain cloning
H-chainR TCTAGAACCTCCACACACAGGAACCAGTGGATAGAC F1-40 H-chain cloning
L-chainF3 GATATCCACCATGGAGTCACAGACTCAGGTCTTTGTA F1-40 L-chain cloning
H-chainF3 GATATCCACCATGGCTGTCTTGGGGCTGCTCTTCT F1-40 H-chain cloning
M13F GTAAAACGACGGCCAG seq. pCR4 plasmids
M13R CAGGAAACAGCTATGAC seq. pCR4 plasmids
pGS-F CAAATTGATAAGTACTTGAAATCC seq. pGS-21a plasmids
pGS-R GCTAGTTATTGCTCAGAGG seq. pGS-21a plasmids
Sites for restriction enzymes BamHI (GGATCC), XhoI (CTCGAG), XbaI (TCTAGA) and EcoRV (GATATC) are shown underlined. Stop codons are shown in bold, either in the
59 to 39 (TAA) or 39 to 59 (TTA) orientation. The third column indicates which peptide fragments each primer was used to construct, or where the primer was used to
clone the heavy and light chain variable regions of F1-40. Primers used only for sequencing are indicated by the abbreviation ‘‘seq.’’
doi:10.1371/journal.pone.0004924.t001
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Femto Maximum Sensitivity Substrate (Pierce) and incubated for
3 min at room temperature with gentle agitation. Luminescent
counts were recorded using a Wallac Victor 2 Multilabel Counter
(PerkinElmer Inc., Waltham, MA). The percentage inhibition of
binding was calculated by the formula (1-B/B0)6100, where
B=luminescent counts at each concentration of fusion peptide in
solution and B0=luminescent counts at 0 mg/mL fusion peptide
in solution.
Phage Display
The Ph.D.-C7C Phage Display Peptide Library Kit (New
England BioLabs) was used to pan against 60 mm polystyrene
dishes coated with antibody F1-40, to identify peptide ligands to
F1-40, according to manufacturer’s instructions. The M13 phage
displays a randomized amino acid heptamer between two cysteine
residues on the pIII minor coat protein. The cysteine residues form
a disulphide bond, resulting in the heptamer being presented as
constrained loop. Four series of panning and three phage
amplification stages were carried out, prior to the growth and
sequencing of individual plaques of the phage. A total of twelve
clonal plaques from the 4
th pan were picked for sequencing.
Cloning and sequencing of antibody variable regions
The method used here for the cloning and sequencing of
variable regions for antibody heavy and light chains is based upon
the method described fully in Current Protocols in Immunology
[26]. Significant changes from this methodology are described
here.
Hybridoma cells for F1-40 production were grown as previously
described [20]. Culture volumes of 5 mL were centrifuged at
120006g for 1 min to collect the cells. mRNA was purified from
the cells using Trizol Reagent (Invitrogen), according to
manufacturer’s instructions. cDNA was transcribed into mRNA
using primers H-chainR and L-chainR, and AMV reverse
transcriptase according to manufacturer’s instructions (Promega,
Madison, WI) The cDNA was amplified by PCR using Phusion
DNA polymerase and the appropriate pairs of primers (H-chain R
and F3; L-chain R and F3). The cDNA was gel purified, then
treated using the MasterTaq Kit (Eppendorf North America,
Westbury, NY) according to manufacturer’s instructions to add A-
overhangs to the DNA. The cDNA was then cloned into plasmid
pCR4-TOPO, and transformed into TOP10 cells. Six individual
colonies of E. coli harboring pCR4-H-chain and pCR4-L-chain
were picked, grown and prepared for sequencing as described
earlier.
Computer tools
All DNA and amino acid sequence analysis was carried out
using the tools of the Biology Workbench, Version 3.2 (http://
workbench.sdsc.edu San Diego Supercomputer Center, University
of California, San Diego, CA). The three-dimensional diagrams of
BoNT/A were generated using the crystal structure of BoNT/A
[7]) manipulated with the MBT Protein Workshop (RCSB Protein
Data Bank, www.rcsb.org/pdb).
Results
Binding of F1-40 to peptide fragments of the BoNT/A
light chain
Seven recombinant peptide fragments of BoNT/A light chain
(Lc, L1, L2, L1-1, L1-2, L1-3, L1-4) are shown in Figure 1. These
recombinant peptides were expressed as fusions to glutathione-S-
transferase (GST). The relative molecular weights (rMW) of these
recombinant peptide-GST proteins, observed by SDS-PAGE and
silver staining, are shown in Figure 2, panels A and C. In each
case, the rMW corresponds to that predicted for the recombinant
peptide-GST protein. Results from Western blot analyses are
shown in panels B and D. Clearly, F1-40 bound to the light-chain
fragment (Lc) and to subfragment L1, but binding to L2 was not
detected (Figure 2, Panel B). The L1 peptide fragment corresponds
to amino acids M1 to L200. This region was further subdivided by
generating four additional recombinant peptide fragments L1-1
Figure 1. Peptide fragments of BoNT/A light chain. Diagram is
drawn to scale to facilitate size and location comparison between
peptide fragments. Peptide fragments were expressed as fusions to GST
at the N-terminal. N- and C-terminal amino acids of each peptide
fragment are indicated.
doi:10.1371/journal.pone.0004924.g001
Table 2. Mutations made in the putative F1-40 epitope
region on plasmid pGS-Lc.
Vector Light chain, from T-125 to Q-162
pGS-Lc TELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQ
pGS-Lc-D TELKVIDTN---------------LNLVIIGPSADIIQ
pGS-Lc-QPD TELKVIDTNCINVIGGGGSYRSEELNLVIIGPSADIIQ
pGS-Lc-RS TELKVIDTNCINVIQPDGSYGGEELNLVIIGPSADIIQ
All four vectors shown above harbored and expressed the entire BoNT/A light
chain (P-1 to K-438), but only the mutated region (T-125 to Q-162) is shown
here. All other amino acids within the light chain were not mutated. Dashes
indicate that amino acids have been deleted. Single amino acid mutations are
indicated in bold.
doi:10.1371/journal.pone.0004924.t002
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was observed to bind two of these recombinant peptide fragments,
L1-3 and L1-4 (Figure 2, Panel D). In contrast, binding to L1-1
and L1-2 was not detected. These results, particularly antibody
binding to L1-3, suggest that the epitope for F1-40 resides between
amino acids T125 and L200.
Fine epitope maping of F1-40 using heptamer peptide
ligands identified by phage display
In an effort to further localize the epitope for F1-40, binding to
a random phage display library of heptamer peptides was
evaluated. Following four rounds of panning, twelve clonal
plaques picked for sequencing. One plaque failed to yield
sequence, and the remaining eleven sequences of the heptamer
peptide ligands for F1-40 are shown, with their frequency of
occurrence, in Table 3. The most common motif, SSAFYPK,
found in eight of the eleven plaques sequenced, did not readily
map to a putative epitope region on the L1-3 peptide fragment, or
to any other region on the light chain of BoNT/A and most
probably represents a mimotope. In contrast, the motif QPDRS,
common to the remaining three heptamer sequences, when
mapped onto the three-dimensional structure of BoNT/A [7]
corresponded to the turn (Q139, P140, D141) between ß4–ß5 and
the first two amino acids (R144, S145) of ß5. While R144 and
S145 are separated from amino acids QPD (the very tip of the
loop) they are brought into close proximity to each other by the
tertiary structure of the toxin (See Figure 3).
Binding of F1-40 to mutants of the Lc peptide fragment
We developed mutant recombinant Lc peptides carrying
specific amino acid deletions or substitutions within the region
identified via phage display (Table 2). The region spanning from
C134 to E148 (ß4–ß5) forms a looped structure, the tip of which
corresponds to Q139-P140-D141. The entire loop was deleted
from the recombinant peptide Lc to form mutant peptide Lc-D.I n
mutant peptide Lc-QPD the amino acids Q139, P140 and D141
were all mutated to glycine. In mutant peptide Lc-RS the amino
acids R145 and S146 were both mutated to glycine. Panel A in
Figure 4 shows a silver stained gel of the Lc peptide fragment and
the three mutant peptides. As a control, a polyclonal anti-BoNT/
A toxoid antiserum was used in a Western blot, which clearly
bound the Lc peptide and all three mutant peptides (Panel B).
Binding of F1-40 to these mutant peptides is shown by Western
blot in Panel C. F1-40 bound the wild-type Lc peptide and the
mutated peptide Lc-RS, but binding to mutated peptides Lc-D and
to Lc-QPD was not detected. These data demonstrate that the
mutation of the Q139, P140, D141 motif to GGG decreases F1-40
binding to a level which was not detected by Western blotting.
Competition ELISA
Competition ELISA assays were performed to better quantify
the differences of antibody binding to the mutant peptides
observed in the above Western blotting experiments. Results from
these experiments are shown in Figure 5. Peptide Lc was the most
effective at competing binding of F1-40 to immobilized Lc, with
50% inhibition achieved at a concentration of ,3.5 mg/mL.
Mutant peptide Lc-RS was the next most effective competitor
resulting in 50% inhibition of control activity at ,24 mg/mL,
roughly 7-fold higher than that observed for the recombinant Lc
peptide. Finally, mutants Lc-D and Lc-QPD did not compete for
F1-40 binding under these conditions, even at the highest
concentration of peptide used (60 mg/mL).
F1-40 heavy and light chain variable region sequences
The cDNA sequences of the heavy and light chain variable
regions for F1-40 are shown in Figure 6. The nucleotide sequence
of the entire cloned regions is shown, with the corresponding
amino acids shown from the start of the leader peptide to the end
Figure 2. Binding of F1-40 to peptide fragments of BoNT/A light chain. A and C, Light chain fragment-GST fusion peptides separated by gel
electrophoresis and stained with Silver Stain. B and D, Corresponding Western Blots using F1-40 for primary detection. Fusion peptide size is
indicated in kDa.
doi:10.1371/journal.pone.0004924.g002
Table 3. Amino acid sequences identified using phage
display against F1-40.
Heptamer sequence Frequency
SSAFYPK 8
TRQPDRS 1
TLQPDRS 1
SLQPDRS 1
The sequences of the heptamer peptide ligands to mAb F1-40 were identified
using the Ph.D.-C7C Phage Display Peptide Library Kit (New England BioLabs
Inc.) to pan against mAb F1-40. Twelve clonal phage plaques were sequenced,
one failed to yield sequence, and the frequency of the heptamer sequences
observed is shown.
doi:10.1371/journal.pone.0004924.t003
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sequences, framework regions, complementarity determining
regions (CDRs) and J-regions were identified by inspecting the
alignment of the F1-40 heavy and light chains to other antibody
sequences [26–30]. The nucleotide sequence reported was
identical across the six individual colonies of E. coli harboring
either pCR4-L-chain or pCR4-H-chain that were analyzed.
EMBL Nucleotide Sequence Database accession numbers for
these sequences are FM177889 and FM177890, for the light and
heavy chains, respectively.
Discussion
The epitope of mAb F1-40 was mapped to the exposed loop
located between ß4-ß5 on the light chain of BoNT/A (Figure 3).
The amino acids QPDRS, identified by phage display experiments
mapped to this region, Q139, P140, and D141 form the tip of the
loop and R145 and S146 are brought into close proximity by the
tertiary structure of BoNT (Figure 3).
Previous studies in our laboratory [20] demonstrated that mAb
F1-40 bound the light chain domain (Lc) of BoNT. To more
clearly define the binding epitope, the Lc domain of BoNT/A as
well as smaller fragments were cloned into E. coli and expressed as
GST fusion proteins (Figure 2). Western blotting experiments
measuring antibody binding to these recombinant peptide
fragments of toxin Lc demonstrated that the epitope for F1-40
Figure 4. Binding of F1-40 to the Lc peptide fragment mutants.
A., Lc peptide fragment mutants separated by gel electrophoresis and
stained with Silver Stain. B, Western Blot using rabbit polyclonal to
Clostridium botulinum A toxoid # 20641 (Abcam Inc.) for primary
detection. C, Western Blot using F1-40 for primary detection. Peptide
size is indicated in kDa.
doi:10.1371/journal.pone.0004924.g004
Figure 3. Location of the QPDRS motif within the BoNT/A holotoxin. A. Space-filled diagram of the three-dimensional model of the
complete BoNT/A holotoxin showing the heavy (dark gray) and light (light gray) chains. QPDRS motif is the colored region within the light chain. B.
Enlarged view of Q139 (red), P140 (blue), D141 (yellow), R145 (green) and S146 (pink) [7].
doi:10.1371/journal.pone.0004924.g003
Figure 5. Competition ELISA for F1-40 by Lc peptide fragment
mutants in solution. The percent inhibition of binding of mAb F1-40
to immobilized Lc peptide fragment on a 96-well plate by various
peptide fragments in solution (¤, Lc; n Lc-D; # Lc-QPD; & Lc-RS) was
calculated by the formula (1-B/B0)6100, where B=luminescent counts
at each concentration of fusion peptide in solution, and B0=lumines-
cent counts at 0 mg/mL fusion peptide in solution. Data is presented61
standard error, n=4.
doi:10.1371/journal.pone.0004924.g005
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Fine epitope mapping by analysis of binding sequences identified
in phage display experiments suggested that a peptide ligand
containing the amino acid motif QPDRS might constitute part or
all of the F1-40 epitope. When these amino acids were mapped
onto the three-dimensional crystal structure of BoNT/A [7], they
formed a compact, almost continuous sequence corresponding to
an external loop (ß4, ß5) region of the molecule (Figure 3). Amino
acids Q139, P140, and D141 form the tip of the loop and are
separated from residues R145 and S146 by three intervening
amino acids. However, the BoNT/A tertiary structure brings these
amino acids R145 and S146 into close proximity of Q139, P140,
and D141. Replacement of R145 and S146 with glycine residues
had no obvious effect on F1-40 binding as illustrated by Western
blot, but competition ELISA experiments revealed a 7-fold
decrease in the relative affinity of mutant Lc-RS for F1-40
compared to the recombinant Lc peptide. These data suggest that
under the conditions of SDS-PAGE, binding is not visibly altered
by mutating R145 and S146. However, the competiton ELISA
data demonstrated that R145 and S146 do contribute in part to
the binding of F1-40 to the light chain of BoNT/A, under the
solution conditions of competition ELISA. Mutation of Q139,
P140 and D141 to glycine residues or eliminating the entire loop
(mutant LcD) abolished binding of F1-40 to the Lc peptide in both
the competition ELISA and Western blotting experiments,
indicating that the QPD triad is necessary for the binding of F1-
40 to the light chain of BoNT/A.
We have previously shown that binding of F1-40 to BoNT
serotypes B through G is undetectable by ELISA [20]. All three
amino acids, Q139, P140, D141, forming the turn of the exposed
loop (ß4–ß5) are exposed to solvent (Figure 3). Analysis of the
amino acid sequence and three-dimensional structure of the light
chain of BoNTs B through G reveals that although a loop is
formed in a similar position on the light chain in all other BoNT
types (except BoNT/C – there is no crystal structure available),
none possess the QPD motif in its entirety [31–35]. It is highly
probable that the inability of F1-40 to bind the other serotypes of
BoNT is due to the absence of a complete QPD motif.
Interestingly, BoNT/G possesses Q144 and P145 (corresponding
to Q139 and P140) but a glycine not aspartate residue at position
Figure 6. Nucleotide and amino acid sequences for the variable regions of F1-40 k-light and heavy chains. The nucleotide sequences
for the entire cloned regions are shown, with the deduced amino acids from the leader sequence to the end of the fourth framework region. The
leader sequence and three complementarity determining regions (CDRs) are shown highlighted in black, with the amino acids of the CDRs shown in
bold. The four framework regions are shown highlighted in light gray, with the amino acids of the J-regions of both light and heavy chains shown
underlined, within the fourth framework region. EMBL online Accession #s FM177889 & FM177890.
doi:10.1371/journal.pone.0004924.g006
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leading to speculation about the possible role that D141 might
play in determining the specificity of F1-40 to BoNT/A [20,34].
Using a series of overlapping synthetic peptides Dolimbek et al.
[36] successfully mapped continuous regions of BoNT/B recog-
nized by antibodies derived from human, horse and mouse sera.
Such experiments can identify immunodominant areas of a
protein and they have often been used to identify antibody
binding epitopes. However, this approach only detects linear
epitopes and overlooks complex, conformational epitopes. Using
phage display libraries expressing BoNT Hc gene fragments, the
epitopes of two Hc-specific anti-BoNT antibodies were identified
[37]. Levy et al. [26] reported the effective use of a randomly
mutated BoNT/A heavy chain library, displayed on the surface of
yeast cells, to identify single amino acids important in the epitopes
of anti-BoNT/A monoclonal antibodies. In the absence of such
libraries for the BoNT/A light chain, we have nonetheless been
able to characterize the epitope of F1-40 to a similarly high
resolution. We expect our experimental approach to increase the
likelihood of identifying epitopes of other antibodies in the future,
and to facilitate their characterization at the single amino acid
level.
Although the phage display analysis yielded the sequence
QPDRS, it also provided the anomalous motif SSAFYPK in eight
of the eleven sequenced plaques. Unlike the sequence QPDRS,
this second sequence could not be mapped onto the light chain of
BoNT/A, and it probably represents a mimotope of the F1-40
epitope. Mimotopes are commonly identified by phage display,
and this faculty has been widely exploited to generate potential
peptide vaccine candidates [22,38–39]. When using phage display
to search for an epitope, multiple mimotopes that bind a
monoclonal antibody can be selected, and it is necessary to
examine every mimotope to identify an epitope region [40,41].
Supporting evidence defining an epitope, such as the Lc peptide
mutagenesis data presented in this study, must be included in the
analysis before assigning an epitope to an antibody. The
assignment of an epitope motif to F1-40 including Q139, P140,
D141, R145 and S146 is consistent with the BoNT serotype A
specificity of F1-40.
Sequence analysis of the cDNA derived from the mRNA coding
for the heavy and light chains of F1-40 reveals features that are
typical of mouse monoclonals antibodies [28,30,42]. On the k-light
chain, the section GVDGDIVMTQ from G29 to Q38 is a repeat
of a preceding section from G17 to Q26, and forms the junction
between the leader sequence and first framework region of the
mature light chain. This repeat is not always present in k-light
chains. The J-region of the heavy chain, TLVTVSA, is type 3 and
the J-region of the k-light chain, TKLEIK, is type 2 [27].
In conclusion, we have localized the epitope of anti-BoNT/A
mAb F1-40 to the exposed loop between ß4-ß5 regions. Both the
our phage display and mutant-binding data suggest that amino
acids Q139, P140, and D141, located at the tip of this loop, are
critical for antibody binding. In addition, we report the cDNA and
deduced amino acid sequences the variable and J-regions of the
antibody’s heavy and light chains. The epitope assignment to a
specific loop not only provides important insight into the nature of
the interaction between F1-40 and BoNT/A, but also is highly
useful for the future development of F1-40 as an integral
component of a test for BoNT/A contamination of food.
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